Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines
Hikma Pharmaceuticals (OTC:HKMPY) has announced a significant $1 billion investment to expand its US manufacturing and R&D capabilities by 2030. The initiative, dubbed "America Leans on Hikma," builds upon the company's 34-year presence in the US market and aims to enhance domestic production of essential generic medicines.
The company currently operates facilities in Columbus and Cleveland, Ohio, and Cherry Hill and Dayton, New Jersey. Hikma has invested over $4 billion in the past 15 years and has the capacity to produce more than 12 billion finished doses annually. As a top three US supplier of sterile injectable medicines, Hikma maintains a portfolio of over 800 medicines, including more than 180 injectable products.
Hikma Pharmaceuticals (OTC:HKMPY) ha annunciato un importante investimento di 1 miliardo di dollari per ampliare le sue capacità produttive e di ricerca e sviluppo negli Stati Uniti entro il 2030. L'iniziativa, denominata "America Leans on Hikma", si basa sulla presenza trentennale dell'azienda nel mercato statunitense e punta a potenziare la produzione nazionale di farmaci generici essenziali.
Attualmente l'azienda gestisce stabilimenti a Columbus e Cleveland, Ohio, e Cherry Hill e Dayton, New Jersey. Hikma ha investito oltre 4 miliardi di dollari negli ultimi 15 anni e ha la capacità di produrre più di 12 miliardi di dosi finite ogni anno. Come uno dei primi tre fornitori statunitensi di medicinali iniettabili sterili, Hikma offre un portafoglio di oltre 800 farmaci, inclusi più di 180 prodotti iniettabili.
Hikma Pharmaceuticals (OTC:HKMPY) ha anunciado una importante inversión de 1.000 millones de dólares para expandir sus capacidades de fabricación e I+D en Estados Unidos para 2030. La iniciativa, llamada "America Leans on Hikma", se basa en los 34 años de presencia de la empresa en el mercado estadounidense y busca fortalecer la producción nacional de medicamentos genéricos esenciales.
La compañía actualmente opera instalaciones en Columbus y Cleveland, Ohio, y Cherry Hill y Dayton, Nueva Jersey. Hikma ha invertido más de 4.000 millones de dólares en los últimos 15 años y tiene la capacidad de producir más de 12.000 millones de dosis terminadas anualmente. Como uno de los tres principales proveedores estadounidenses de medicamentos inyectables estériles, Hikma mantiene un portafolio de más de 800 medicamentos, incluidos más de 180 productos inyectables.
Hikma Pharmaceuticals (OTC:HKMPY)는 2030년까지 미국 내 제조 및 연구개발 역량을 확장하기 위해 10억 달러 규모의 투자를 발표했습니다. 'America Leans on Hikma'라는 이름의 이 이니셔티브는 회사가 미국 시장에 진출한 지 34년의 역사를 바탕으로 필수 제네릭 의약품의 국내 생산을 강화하는 것을 목표로 합니다.
현재 이 회사는 오하이오주 콜럼버스와 클리블랜드, 뉴저지주 체리 힐과 데이턴에 시설을 운영하고 있습니다. Hikma는 지난 15년간 40억 달러 이상을 투자했으며 연간 120억 개 이상의 완제품 투여량을 생산할 수 있는 능력을 보유하고 있습니다. 미국 내 멸균 주사제 상위 3대 공급업체 중 하나로서 Hikma는 800종 이상의 의약품 포트폴리오를 갖추고 있으며, 그중 180종 이상의 주사제 제품을 포함하고 있습니다.
Hikma Pharmaceuticals (OTC:HKMPY) a annoncé un investissement important de 1 milliard de dollars pour développer ses capacités de production et de recherche et développement aux États-Unis d'ici 2030. Cette initiative, nommée "America Leans on Hikma", s'appuie sur les 34 ans de présence de l'entreprise sur le marché américain et vise à renforcer la production nationale de médicaments génériques essentiels.
L'entreprise exploite actuellement des sites à Columbus et Cleveland, Ohio, ainsi qu'à Cherry Hill et Dayton, New Jersey. Hikma a investi plus de 4 milliards de dollars au cours des 15 dernières années et dispose d'une capacité de production de plus de 12 milliards de doses finies par an. En tant que troisième fournisseur américain de médicaments injectables stériles, Hikma possède un portefeuille de plus de 800 médicaments, dont plus de 180 produits injectables.
Hikma Pharmaceuticals (OTC:HKMPY) hat eine bedeutende Investition von 1 Milliarde US-Dollar angekündigt, um seine Produktions- und F&E-Kapazitäten in den USA bis 2030 auszubauen. Die Initiative mit dem Namen "America Leans on Hikma" baut auf der 34-jährigen Präsenz des Unternehmens auf dem US-Markt auf und zielt darauf ab, die heimische Produktion wichtiger generischer Arzneimittel zu stärken.
Das Unternehmen betreibt derzeit Einrichtungen in Columbus und Cleveland, Ohio, sowie Cherry Hill und Dayton, New Jersey. Hikma hat in den letzten 15 Jahren über 4 Milliarden US-Dollar investiert und verfügt über die Kapazität, jährlich mehr als 12 Milliarden fertige Dosen herzustellen. Als einer der drei größten US-Lieferanten von sterilen injizierbaren Arzneimitteln hält Hikma ein Portfolio von über 800 Medikamenten, darunter mehr als 180 injizierbare Produkte.
- Substantial $1 billion investment commitment through 2030 for US manufacturing expansion
- Current capacity to produce over 12 billion finished doses annually
- Strong market position as top 3 US supplier of sterile injectable medicines
- Extensive portfolio of 800+ medicines including 180+ injectable products
- Proven track record of FDA quality inspections and addressing drug shortages
- None.
Insights
Hikma's $1B US expansion strengthens domestic supply chain position, boosting production capacity and competitiveness in generic medicines market.
Hikma's
The expansion targets both R&D and manufacturing across facilities in Ohio and New Jersey, which should strengthen Hikma's competitive position in two key segments: generic pharmaceuticals and sterile injectables. Notably, the company has already achieved a top three position in US sterile injectables by volume, with 180 injectable products currently in its portfolio.
This investment is particularly strategic given the ongoing national focus on pharmaceutical supply chain security and domestic manufacturing capabilities. Hikma's emphasis on its role in addressing drug shortages and its track record with FDA inspections positions it favorably amid policy discussions about reducing dependency on foreign pharmaceutical manufacturing.
The company's bipartisan political support, evidenced by the presence of Representatives from both parties at the announcement, also suggests potential regulatory tailwinds. The backing from Rep. Carter, who chairs the American-Made Medicines Caucus, indicates alignment with current political priorities around domestic pharmaceutical production.
This expansion should enhance Hikma's economies of scale, potentially improving margins while simultaneously increasing its capacity to capture greater market share in the competitive US generics space.
Next phase builds on 34+ years of serving the needs of US patients and healthcare providers
Hikma has operated in the US since 1991 and has spent more than
Elected officials including US Rep. Mike Carey (OH-15) and US Rep. Buddy Carter (GA-01) joined Hikma at a special groundbreaking event held at the Company's state-of-the-art pharmaceutical manufacturing and R&D facility in
America Leans on Hikma represents the Company's latest efforts to increase the volume of essential medicines it develops and produces across its R&D and manufacturing sites in
"We are proud to continue our ongoing investments in US manufacturing and R&D to better serve the needs of American patients," said Dr. Hafrun Fridriksdottir, President, Hikma Rx. "Hikma and our 2,300 dedicated US people are committed to supporting healthier communities nationwide by providing Americans with a steady and reliable supply of domestically produced quality medicines."
Dr. Bill Larkins, President, Hikma Injectables added, "Over the past 15 years Hikma has grown to become a top three US supplier of sterile injectable medicines by volume with more than 180 injectable products in our portfolio and a growing pipeline. This new phase of US investment will enhance and expand our sterile injectables production capabilities and enable us to continue providing our broad portfolio of essential medicines to US patients."
"As a pharmacist and Chairman of the American-Made Medicines Caucus, I understand the crucial role Hikma and other generic manufacturers play in delivering affordable and accessible medicines to Americans. It's important that we onshore the production of these critical drugs. I will continue working with Hikma to strengthen our national security and public health by making life-saving generic medications here, in America, and applaud them for their announcement today," said Rep. Buddy Carter.
"Hikma continues to invest in American workers and I am thrilled that they have chosen to continue that commitment here in
Hikma remains steadfast in its mission to provide affordable and accessible health care solutions. With this continued investment, Hikma reaffirms its commitment to ensuring a reliable supply of essential medications for all Americans.
Contacts :
Hikma Pharmaceuticals PLC
Investors Susan Ringdal EVP, Strategic Planning and Global Affairs | +44 (0)20 7399 2760/ +44 7776 477050 |
Media Steven Weiss US Communications | +1 732 788 8279 |
About Hikma
(LSE: HIK) (NASDAQ
Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the
View original content to download multimedia:https://www.prnewswire.com/news-releases/hikma-pharmaceuticals-usa-announces-1-billion-of-new-us-investment-to-further-expand-its-domestic-manufacturing-and-development-of-essential-generic-medicines-302493824.html
SOURCE Hikma Pharmaceuticals USA Inc.
FAQ
What is the size of Hikma Pharmaceuticals' (HKMPY) new US investment and when will it be completed?
How many medicines does Hikma currently produce in the US?
Where are Hikma's US manufacturing facilities located?
How much has Hikma invested in US operations over the past 15 years?
How many employees does Hikma have in the US?
